This isn't a good day for investors in Grail (NASDAQ: GRAL). The stock declined more than 50% by 1:30 p.m. today. The move comes on the day of its fourth-quarter earnings results, but more importantly, the release of its top-line results from a major trial of its Galleri multi-cancer early detection (MCED) test in England's National Health Service (NHS). As you have already surmised, the trial did not go as planned. What went wrong The first bullet point of the results release is what investors are focusi ...